Linderalactone mitigates diabetic renal injury by inhibiting macrophage inflammation via the Dectin1/Syk/ CARD9 / IRF5 / NF ‐ κB pathway
Journal of Diabetes Investigation · 2026-03 · 17 (3) · 395-410
DOI: 10.1111/jdi.70222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 08.01.2026. Verfasst von Hao Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First People's Hospital of Yongkang, Yongkang, Zhejiang Province, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Macrophages, Inflammation, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Key Major Science and Technology Project of Jinhua City.
Abstract (Originalsprache)
Background
Inflammation plays an essential role in the pathogenesis of diabetic nephropathy (DN). Linderalactone (LNL), as a natural sesquiterpene lactone, has been discovered to have anti‐inflammatory activation. However, the effects of linderalactone on diabetes‐associated renal damage remain unclear.
Methods
This study investigated the effects of LNL on renal function and inflammation in diabetic mice. Renal function, collagen deposition, and fibrosis were assessed. RNA‐sequencing was performed to identify molecular pathways affected by LNL. The Dectin1‐related pathway was analyzed in kidney tissues and RAW264.7 cells. Dectin1‐deficient and Dectin1‐overexpressing models were used to confirm the mechanism of LNL.
Results
LNL improved renal function, reduced collagen deposition and fibrosis in diabetic mice without affecting blood glucose levels. RNA‐sequencing revealed that LNL primarily impacted the Dectin1 pathway. It inhibited the Dectin1/Syk/CARD9/IRF5/NF‐κB pathway, reduced macrophage and neutrophil infiltration, and suppressed inflammatory cytokine expression. Dectin1 knockdown mimicked these effects, while Dectin1 overexpression reversed them.
Conclusions
LNL alleviates DN via suppression of macrophage inflammation by mediating the Dectin1/Syk/CARD9/IRF5/NF‐κB signaling pathway, highlighting its potential as a therapeutic agent for diabetes‐associated renal injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The First People's Hospital of Yongkang, Yongkang, Zhejiang Province, China.
- Department of Traditional Chinese Medicine, The First People's Hospital of Yongkang, Yongkang, Zhejiang Province, China.
ORCID-Profile: Xishan Xiong, Huishang Wang
Förderung
- Key Major Science and Technology Project of Jinhua City
Zitieren
APA
Chen, H., Xu, S., Chen, B., Xiong, X., Hu, J., Wu, Y., Wang, T., & Wang, H. (2026). Linderalactone mitigates diabetic renal injury by inhibiting macrophage inflammation via the Dectin1/Syk/ CARD9 / IRF5 / NF ‐ κB pathway. Journal of Diabetes Investigation, 17(3), 395-410. https://doi.org/10.1111/jdi.70222
Vancouver
Chen H, Xu S, Chen B, Xiong X, Hu J, Wu Y, et al. Linderalactone mitigates diabetic renal injury by inhibiting macrophage inflammation via the Dectin1/Syk/ CARD9 / IRF5 / NF ‐ κB pathway. Journal of Diabetes Investigation. 2026;17(3):395-410. doi:10.1111/jdi.70222
BibTeX
@article{Chen2026,
author = {Chen, Hao and Xu, Sheng and Chen, Bingrong and Xiong, Xishan and Hu, Jinrui and Wu, Yuhong and Wang, Tianrui and Wang, Huishang},
title = {Linderalactone mitigates diabetic renal injury by inhibiting macrophage inflammation via the Dectin1/Syk/ CARD9 / IRF5 / NF ‐ κB pathway},
journal = {Journal of Diabetes Investigation},
year = {2026},
volume = {17},
number = {3},
pages = {395--410},
doi = {10.1111/jdi.70222}
}
EUVIMED